Necrotizing Enterocolitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major necrotizing enterocolitis markets reached a value of US$ 3.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.5 Billion by 2034, exhibiting a growth rate (CAGR) of 3.92% during 2024-2034.
The necrotizing enterocolitis market has been comprehensively analyzed in IMARC's new report titled "Necrotizing Enterocolitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Necrotizing enterocolitis refers to a serious medical condition that primarily affects premature infants, especially those born before 32 weeks of gestation. It is characterized by inflammation and tissue death in the intestine, particularly in the colon and small intestine. The indications associated with this condition can vary in severity but often include feeding intolerance, abdominal distension, blood in the stool, lethargy, etc. In some cases, infants suffering from the ailment may exhibit signs of sepsis, such as a high temperature or an unstable heart rate. The diagnosis of necrotizing enterocolitis mainly involves a combination of clinical evaluation, laboratory tests, and imaging studies. The healthcare provider may also utilize abdominal scans to identify signs of intestinal damage or pneumatosis, which is the presence of gas in the intestinal wall. Additionally, blood tests might be conducted to aid in assessing the patient’s overall health and detecting indications of infection or organ dysfunction.
The increasing cases of premature births, which make infants prone to inflammation and infection due to immature gastrointestinal systems, are primarily driving the necrotizing enterocolitis market. In addition to this, the inflating utilization of effective treatments, such as antibiotics and intravenous fluids, to manage the ailment and prevent further complications is creating a positive outlook for the market. These therapies help to combat infections as well as maintain hydration and electrolyte balance in patients. Moreover, the widespread adoption of specialized feeding strategies, including parenteral nutrition and the slow advancement of enteral feeds, which can reduce the risk of disease development, is further bolstering the market growth. Apart from this, the rising usage of advanced medical technologies, such as imaging techniques like X-rays and ultrasound, since they aid in the accurate diagnosis of necrotizing enterocolitis cases, is acting as another significant growth-inducing factor. Additionally, the escalating implementation of preventive measures, including strict hygiene protocols and careful monitoring of high-risk neonates in neonatal intensive care units to curb the incidence of illness, is also augmenting the market growth. Furthermore, the rising R&D activities in the fields of regenerative drugs and stem cell therapies, which offer promising potential for improved treatment outcomes, are expected to drive the necrotizing enterocolitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the necrotizing enterocolitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for necrotizing enterocolitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the necrotizing enterocolitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the necrotizing enterocolitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the necrotizing enterocolitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current necrotizing enterocolitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the necrotizing enterocolitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the necrotizing enterocolitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the necrotizing enterocolitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with necrotizing enterocolitis across the seven major markets?
What is the size of the necrotizing enterocolitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of necrotizing enterocolitis?
What will be the growth rate of patients across the seven major markets?
Necrotizing Enterocolitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for necrotizing enterocolitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the necrotizing enterocolitis market?
What are the key regulatory events related to the necrotizing enterocolitis market?
What is the structure of clinical trial landscape by status related to the necrotizing enterocolitis market?
What is the structure of clinical trial landscape by phase related to the necrotizing enterocolitis market?
What is the structure of clinical trial landscape by route of administration related to the necrotizing enterocolitis market?
The necrotizing enterocolitis market has been comprehensively analyzed in IMARC's new report titled "Necrotizing Enterocolitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Necrotizing enterocolitis refers to a serious medical condition that primarily affects premature infants, especially those born before 32 weeks of gestation. It is characterized by inflammation and tissue death in the intestine, particularly in the colon and small intestine. The indications associated with this condition can vary in severity but often include feeding intolerance, abdominal distension, blood in the stool, lethargy, etc. In some cases, infants suffering from the ailment may exhibit signs of sepsis, such as a high temperature or an unstable heart rate. The diagnosis of necrotizing enterocolitis mainly involves a combination of clinical evaluation, laboratory tests, and imaging studies. The healthcare provider may also utilize abdominal scans to identify signs of intestinal damage or pneumatosis, which is the presence of gas in the intestinal wall. Additionally, blood tests might be conducted to aid in assessing the patient’s overall health and detecting indications of infection or organ dysfunction.
The increasing cases of premature births, which make infants prone to inflammation and infection due to immature gastrointestinal systems, are primarily driving the necrotizing enterocolitis market. In addition to this, the inflating utilization of effective treatments, such as antibiotics and intravenous fluids, to manage the ailment and prevent further complications is creating a positive outlook for the market. These therapies help to combat infections as well as maintain hydration and electrolyte balance in patients. Moreover, the widespread adoption of specialized feeding strategies, including parenteral nutrition and the slow advancement of enteral feeds, which can reduce the risk of disease development, is further bolstering the market growth. Apart from this, the rising usage of advanced medical technologies, such as imaging techniques like X-rays and ultrasound, since they aid in the accurate diagnosis of necrotizing enterocolitis cases, is acting as another significant growth-inducing factor. Additionally, the escalating implementation of preventive measures, including strict hygiene protocols and careful monitoring of high-risk neonates in neonatal intensive care units to curb the incidence of illness, is also augmenting the market growth. Furthermore, the rising R&D activities in the fields of regenerative drugs and stem cell therapies, which offer promising potential for improved treatment outcomes, are expected to drive the necrotizing enterocolitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the necrotizing enterocolitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for necrotizing enterocolitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the necrotizing enterocolitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the necrotizing enterocolitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the necrotizing enterocolitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current necrotizing enterocolitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the necrotizing enterocolitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the necrotizing enterocolitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the necrotizing enterocolitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with necrotizing enterocolitis across the seven major markets?
What is the size of the necrotizing enterocolitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of necrotizing enterocolitis?
What will be the growth rate of patients across the seven major markets?
Necrotizing Enterocolitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for necrotizing enterocolitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the necrotizing enterocolitis market?
What are the key regulatory events related to the necrotizing enterocolitis market?
What is the structure of clinical trial landscape by status related to the necrotizing enterocolitis market?
What is the structure of clinical trial landscape by phase related to the necrotizing enterocolitis market?
What is the structure of clinical trial landscape by route of administration related to the necrotizing enterocolitis market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NECROTIZING ENTEROCOLITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NECROTIZING ENTEROCOLITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NECROTIZING ENTEROCOLITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NECROTIZING ENTEROCOLITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NECROTIZING ENTEROCOLITIS - UNMET NEEDS
10 NECROTIZING ENTEROCOLITIS - KEY ENDPOINTS OF TREATMENT
11 NECROTIZING ENTEROCOLITIS - MARKETED PRODUCTS
11.1 List of Necrotizing Enterocolitis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 NECROTIZING ENTEROCOLITIS - PIPELINE DRUGS
12.1 List of Necrotizing Enterocolitis Pipeline Drugs Across the Top 7 Markets
12.1.1 IBP-9414 - Infant Bacterial Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 STP206 - Leadiant Biosciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 NECROTIZING ENTEROCOLITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 NECROTIZING ENTEROCOLITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NECROTIZING ENTEROCOLITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Necrotizing Enterocolitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Necrotizing Enterocolitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Necrotizing Enterocolitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Necrotizing Enterocolitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Necrotizing Enterocolitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Necrotizing Enterocolitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Necrotizing Enterocolitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Necrotizing Enterocolitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Necrotizing Enterocolitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Necrotizing Enterocolitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Necrotizing Enterocolitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Necrotizing Enterocolitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Necrotizing Enterocolitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Necrotizing Enterocolitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Necrotizing Enterocolitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Necrotizing Enterocolitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
16 NECROTIZING ENTEROCOLITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NECROTIZING ENTEROCOLITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NECROTIZING ENTEROCOLITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NECROTIZING ENTEROCOLITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NECROTIZING ENTEROCOLITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NECROTIZING ENTEROCOLITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NECROTIZING ENTEROCOLITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NECROTIZING ENTEROCOLITIS - UNMET NEEDS
10 NECROTIZING ENTEROCOLITIS - KEY ENDPOINTS OF TREATMENT
11 NECROTIZING ENTEROCOLITIS - MARKETED PRODUCTS
11.1 List of Necrotizing Enterocolitis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 NECROTIZING ENTEROCOLITIS - PIPELINE DRUGS
12.1 List of Necrotizing Enterocolitis Pipeline Drugs Across the Top 7 Markets
12.1.1 IBP-9414 - Infant Bacterial Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 STP206 - Leadiant Biosciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 NECROTIZING ENTEROCOLITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 NECROTIZING ENTEROCOLITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NECROTIZING ENTEROCOLITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Necrotizing Enterocolitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Necrotizing Enterocolitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Necrotizing Enterocolitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Necrotizing Enterocolitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Necrotizing Enterocolitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Necrotizing Enterocolitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Necrotizing Enterocolitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Necrotizing Enterocolitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Necrotizing Enterocolitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Necrotizing Enterocolitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Necrotizing Enterocolitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Necrotizing Enterocolitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Necrotizing Enterocolitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Necrotizing Enterocolitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Necrotizing Enterocolitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Necrotizing Enterocolitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
16 NECROTIZING ENTEROCOLITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NECROTIZING ENTEROCOLITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NECROTIZING ENTEROCOLITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
